Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs
SL1009 targets a 2025 FDA decision for Pyruvate Dehydrogenase Complex Deficiency (PDCD), while SL1002 advances toward Phase III trials for osteoarthritis knee pain and spasticity Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced multiple updates on its rapidly advancing clinical development portfolio. https://mma.prnewswire.com/media/1704579/Saol_logo_FINAL_Logo.jpg SL1009,Sodium Dichloroacetate (DCA)DCA is an investigational product, that if approved, […]